IDEAS home Printed from https://ideas.repec.org/a/adp/jgjpps/v5y2018i2p47-55.html
   My bibliography  Save this article

The Recent Trend in Bio-Similar Drugs Development

Author

Listed:
  • Sankha Bhattacharya
  • Shreya Naresh Naik
  • Prachi Jitendra Patel
  • Urvi Gopal Mav

    (Department of Pharmaceutics, Rofel Shri G M Bilakhia College of Pharmacy, India)

Abstract

The patent expiry of various biological medicines has led to developed Bio-Similar drugs across the globe. This article reviews the various approved Bio-Similar drugs in India and the challenges of Bio-Similar drugs for getting marketing approval. USFDA guideline clearly said that Bio-Similar drugs are not generic medications nor identical to the innovator medicine and also it’s not ensuring therapeutic equivalence with innovator drug. Getting Bio-Similar product marketing approval is a challenging task. To improve access of Bio-Similar drugs within the US market, US-FDA allows abbreviated pathway for their approval. Recently India is becoming a most preferable destination for Bio-Similar manufacturers, because of Make in India program. Introduction of recombinant technique to prepare Monoclonal antibody based Bio-Similar drug becoming popular within pharmaceutical manufactures because of many recent patent expiries of Biologics. The biologies are produced by cell culture method; hence, chances of variability’s are more as comparable with the chemically synthesized conventional medicine. Therefor it is impossible to produce an identical copy of an innovator product; hence, Bio-Similar is not considered as generic drugs. These drugs are Twin but not a clone of the innovator drug. The Bio-Similar drugs always face challenges regarding verification of the similarity, the interchange ability, unique naming to differentiate the various Bio-Pharmaceutical products, commercial opportunities, IPR and public safety.

Suggested Citation

  • Sankha Bhattacharya & Shreya Naresh Naik & Prachi Jitendra Patel & Urvi Gopal Mav, 2018. "The Recent Trend in Bio-Similar Drugs Development," Global Journal of Pharmacy & Pharmaceutical Sciences, Juniper Publishers Inc., vol. 5(2), pages 47-55, March.
    • Handle: RePEc:adp:jgjpps:v:5:y:2018:i:2:p:47-55
    DOI: 10.19080/GJPPS.2018.05.555660
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555660.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555660.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/GJPPS.2018.05.555660?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jgjpps:v:5:y:2018:i:2:p:47-55. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.